SPY376.70-4.72 -1.24%
DIA309.58-3.41 -1.09%
IXIC12,723.47-274.28 -2.11%

Gilead quarterly revenue rises 26% on remdesivir sales

· 02/04/2021 16:05
Gilead quarterly revenue rises 26% on remdesivir sales

- Gilead Sciences Inc GILD.O posted a 26% rise in quarterly revenue on Thursday, helped by sales of its antiviral drug, remdesivir, which is authorized to treat COVID-19 patients across the world.

Remdesivir brought in $1.9 billion in the fourth quarter ended Dec. 31, above analysts' estimates of $1.34 billion, according to Refinitiv IBES data.


(Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D'Silva)

((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132;))